Breast cancer survivals and hormone therapy: estrogen and melatoninClimacteric is a period of transition between reproductive and non-reproductive periods. It is filled with fears and anxieties. Although many women go through this age phase without any symptoms or significant challenges, others suffer with intense vasomotor symptoms (hot flashes), which can cause perspiration and interfere with sleep if they occur at night1. Also, approximately 80% of breast cancer patients are above 50 years old, which matches with the mean age of menopause1,2. However, the behavior and prognosis of this malign neoplasia may be related to the estrogen status3. It is a concern for menopausal hormone treatment.
Estrogen hormone therapy is known for its benefits, such as alleviating vasomotor symptoms arising from the state of hypoestrogenism. However, long-term use can provide an increased risk of breast cancer, which brings fear for both physicians and women4. This relative risk (RR) of estrogen associated with progestin to develop breast cancer is around 1.255, which is a weak factor. The progestin is important to avoid endometrial proliferative lesions that may progress to cancer6. However, this unopposed estrogen breast cancer RR is not significant in hysterectomized women7.
Regarding the RR of cancer, the values over 1:50 are considered relevant for any event. At this point, hormone therapy would have no relevant impact on the onset of breast cancer compared to familial or genetic risk8. However, the fear is still very great in the perception of women in relation to breast cancer. Non-hormonal therapy could be an alternative, but side effects and lack of improvement are the main reasons for non-adherence to patients8. Therefore, estrogen therapy is still more effective for this treatment.
Some breast cancer survivors experience hot flashes without improvement when treated by the non-hormonal drugs, mainly serotonin reuptake inhibitors, as well as the inhibitors of reuptake of noradrenaline and serotonin and other substances9. It is a great concern to alleviate these symptoms, which affect sleep patterns, professional activities, and quality of life1,2. The hormone therapy with estrogen is a controversial question: it decreases the symptoms, but may impact the prognosis of the patient1-3,8. The HABITS trial showed 2.4 times more risk of new breast cancer events in breast cancer survivors with a cumulative incidence of 22.2% in the group taking hormone replacement versus 8% in the control arm at 5 years10.
Recently, Mendoza et al.11 reported a new view in the use of hormone therapy in the climacteric, including classifying it into categories, which is similar to hormonal contraceptive during the reproductive period by the World Health Organization11. In addition, the authors suggest that hormone therapy with estrogen could be indicated in women with triple negative breast cancer11, but the evidence supporting this conduct is few and the prognosis of this type of breast tumor is lower than that with positive receptor11. These findings were supported by Poggio et al.’s12 meta-analysis of four clinical trials with 4050 patients randomized to receive estrogen/progestogen or tibolone against placebo or no hormone therapy. The hormone replacement increased the risk of breast cancer recurrence by 46%, ranging from 12 to 91% according to the confidence interval, but only in the hormone receptor positive subgroup analysis (HR 1.8, 95%CI 1.15–2.82, p=0.010). The triple negative group had no risk (HR 1.19, 95% CI 1.15–1.77, p=0.39). For these reasons, this proposal is still controversial. However, the North American Menopause Society states that if the patient has decreased quality of life and has tried other non-hormonal treatments without adequate results, hormone therapy should be discussed with the patient13.
In general, estrogen has its proliferative effect on breast tissue due to intracellular signaling after activation of the alpha receptor on the cell membrane, whose pathway involves the mitogenic protein14. In this process, there is interaction with the activation of cyclic AMP and PKA, which are also the target of melatonin signaling15, and this could interfere with the estrogenic mitogenic action in the breast tissue14.
Melatonin has oncostatic actions that are exerted through different mechanisms: indirect effects by reducing ovarian estrogen production; direct anti-estrogenic actions at the level of tumor cells; induction of apoptosis; antioxidant effects; increased anti-neoplastic immunity; reduction of telomerase activity; inhibition of fatty acid uptake and metabolic pathways of fat; and inhibition of angiogenesis16.
Regarding its anti-angiogenic effects, melatonin reduces the expression of vascular-endothelial growth factor (VEGF) mRNA in MCF-7 cells and inhibits proliferation, invasion, and migration of endothelial cells and formation of tubular networks induced by VEGF16-18. Similarly, melatonin indirectly inhibits angiogenesis through the repression of IGF, EGF, and ET-1 (tumor growth factors and tumor angiogenesis enhancers) and decreases the production of ROS, which has an important function in the stabilization of the hypoxia-inducing factor-α during hypoxia16.
In patients with estrogen receptor (ER) positive breast cancer, melatonin appears to have an inhibitory action on estrogen-mediated cells. It presents an anti-cancer effect because of two membrane protein named MT1 receptor and MT2 receptor. The oncostatic effect in breast cancer is achieved by the suppression and inhibition of ER mRNA. Besides that, melatonin also regulates the metabolism of other steroid hormone and nuclear receptor family members, which interferes with the effect of the estrogen on breast tissue19.
Melatonin acts on the sleep of postmenopausal women with breast cancer, but without improvement in vasomotor symptoms20. Furthermore, it seems to have a synergic effect with other anti-neoplastic treatments, with the reduction of toxicity19. Perhaps, a combination of estrogen and melatonin could be beneficial for women with intense vasomotor symptoms. However, there is a need for studies, and perhaps this is the great challenge of the future: optimal hormone replacement in women who have had breast cancer.
REFERENCES
-
1. Soares Júnior JM, Sorpreso IC, Baracat EC. Is hormone therapy during climacteric for all?. Rev Assoc Med Bras (1992). 2015;61(3):191-2. https://doi.org/10.1590/1806-9282.61.03.191
» https://doi.org/10.1590/1806-9282.61.03.191 -
2. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287. https://doi.org/10.3390/cancers13174287
» https://doi.org/10.3390/cancers13174287 -
3. Filho AS, Soares Júnior JM, Arkader J, Maciel GA, Baracat EC. Attitudes and practices about postmenopausal hormone therapy among female gynecologists in Brazil. Maturitas. 2005;51(2):146-53. https://doi.org/10.1016/j.maturitas.2004.06.018
» https://doi.org/10.1016/j.maturitas.2004.06.018 -
4. Sorpreso IC, Soares Júnior JM, Fonseca AM, Baracat EC. Female aging. Rev Assoc Med Bras (1992). 2015;61(6):553-6. https://doi.org/10.1590/1806-9282.61.06.553
» https://doi.org/10.1590/1806-9282.61.06.553 -
5. Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, et al. Prior hormone therapy and breast cancer risk in the women’s health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103-15. https://doi.org/10.1016/j.maturitas.2006.05.004
» https://doi.org/10.1016/j.maturitas.2006.05.004 -
6. Baracat MCP, Baracat EC, Simões RS, Simões MJ, Maciel GAR, Azziz R, et al. Hormonal and metabolic factors influence the action of progesterone on the endometrium of women with polycystic ovary syndrome. Diagnostics (Basel). 2023;13(3):382. https://doi.org/10.3390/diagnostics13030382
» https://doi.org/10.3390/diagnostics13030382 -
7. Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 2. The women’s health initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care. 2011;37(3):165-72. https://doi.org/10.1136/jfprhc-2011-0090
» https://doi.org/10.1136/jfprhc-2011-0090 -
8. Rozenberg S, Panay N, Gambacciani M, Cano A, Gray S, Schaudig K. Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts’ perspective. Expert Rev Clin Pharmacol. 2023;16(6):507-17. https://doi.org/10.1080/17512433.2023.2219056
» https://doi.org/10.1080/17512433.2023.2219056 -
9. Madsen TE, Sobel T, Negash S, Shrout Allen T, Stefanick ML, Manson JE, et al. A review of hormone and non-hormonal therapy options for the treatment of menopause. Int J Womens Health. 2023;15:825-36. https://doi.org/10.2147/IJWH.S379808
» https://doi.org/10.2147/IJWH.S379808 -
10. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475-82. https://doi.org/10.1093/jnci/djn058
» https://doi.org/10.1093/jnci/djn058 -
11. Mendoza N, Ramírez I, Viuda E, Coronado P, Baquedano L, Llaneza P, et al. Eligibility criteria for menopausal hormone therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65-85. https://doi.org/10.1016/j.maturitas.2022.08.008
» https://doi.org/10.1016/j.maturitas.2022.08.008 -
12. Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269-75. https://doi.org/10.1007/s10549-021-06436-9
» https://doi.org/10.1007/s10549-021-06436-9 -
13. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257-71. https://doi.org/10.1097/gme.0b013e31824b970a
» https://doi.org/10.1097/gme.0b013e31824b970a -
14. Gonzalez Valdivia E, Broselid S, Kahn R, Olde B, Leeb-Lundberg LMF. G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms. J Biol Chem. 2017;292(24):9932-43. https://doi.org/10.1074/jbc.M116.765875
» https://doi.org/10.1074/jbc.M116.765875 -
15. Soares JM, Masana MI, Erşahin C, Dubocovich ML. Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. J Pharmacol Exp Ther. 2003;306(2):694-702. https://doi.org/10.1124/jpet.103.049916
» https://doi.org/10.1124/jpet.103.049916 -
16. González-González A, González A, Rueda N, Alonso-González C, Menéndez JM, Martínez-Campa C, et al. Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process. Sci Rep. 2020;10(1):4790. https://doi.org/10.1038/s41598-020-61622-x
» https://doi.org/10.1038/s41598-020-61622-x -
17. Ferreira CS, Carvalho KC, Maganhin CC, Paiotti AP, Oshima CT, Simões MJ, et al. Does melatonin influence the apoptosis in rat uterus of animals exposed to continuous light? Apoptosis. 2016;21(2):155-62. https://doi.org/10.1007/s10495-015-1195-0
» https://doi.org/10.1007/s10495-015-1195-0 -
18. Shiroma ME, Damous LL, Cotrim FP, Roa CL, Cipolla-Neto J, Reiter RJ, et al. Pretreatment with melatonin improves ovarian tissue cryopreservation for transplantation. Reprod Biol Endocrinol. 2021;19(1):17. https://doi.org/10.1186/s12958-021-00705-4
» https://doi.org/10.1186/s12958-021-00705-4 -
19. Kong X, Gao R, Wang Z, Wang X, Fang Y, Gao J, et al. Melatonin: a potential therapeutic option for breast cancer. Trends Endocrinol Metab. 2020;31(11):859-71. https://doi.org/10.1016/j.tem.2020.08.001
» https://doi.org/10.1016/j.tem.2020.08.001 -
20. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145(2):381-8. https://doi.org/10.1007/s10549-014-2944-4
» https://doi.org/10.1007/s10549-014-2944-4
Publication Dates
-
Publication in this collection
25 Sept 2023 -
Date of issue
2023
History
-
Received
24 June 2023 -
Accepted
24 July 2023
